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Upon infection with intracellular bacteria, nucleotide oligomerization domain protein 2 
recognizes bacterial muramyl dipeptide and binds, subsequently, to receptor-interacting 
serine/threonine kinase 2 (RIPK2), which activates immune responses via the nuclear fac-
tor kappa-light-chain enhancer of activated B cells (NF-κB) and extracellular signal-reg-
ulated kinase (ERK) pathways. Activation of RIPK2 depends on its K63 ubiquitination by 
E3 ligases, whereas the deubiquitinating enzyme A20 counter regulates RIPK2 activity 
by cleaving K63-polyubiquitin chains from RIPK2. Here, we newly identify the deubiq-
uitinating enzyme CYLD as a new inhibitor of RIPK2. We show that CYLD binds to and 
removes K63-polyubiquitin chains from RIPK2 in Listeria monocytogenes (Lm) infected 
murine bone marrow-derived macrophages. CYLD-mediated K63 deubiquitination of
RIPK2 resulted in an impaired activation of both NF-κB and ERK1/2 pathways, reduced 
production of proinflammatory cytokines interleukin-6 (IL-6), IL-12, anti-listerial reactive 
oxygen species (ROS) and nitric oxide (NO), and, finally, impaired pathogen control. In 
turn, RIPK2 inhibition by siRNA prevented activation of NF-κB and ERK1/2 and com-
pletely abolished the protective effect of CYLD deficiency with respect to the production 
of IL-6, NO, ROS, and pathogen control. Noteworthy, CYLD also inhibited autophagy 
of Listeria in a RIPK2-ERK1/2-dependent manner. The protective function of CYLD
deficiency was dependent on interferon gamma (IFN-γ) prestimulation of infected mac-
rophages. Interestingly, the reduced NF-κB activation in CYLD-expressing macrophages 
limited the protective effect of IFN-γ by reducing NF-κB-dependent signal transducers 
and activators of transcription-1 (STAT1) activation. Taken together, our study identifies 
CYLD as an important inhibitor of RIPK2-dependent antibacterial immune responses in 
macrophages.
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inTrODUcTiOn
Macrophages play a crucial role in the innate immune response 
including sensing and phagocytosis of bacterial pathogens at the 
site of infection (1). In bacterial infections, phagocyte activation 
is augmented by type II interferon (IFN-γ) produced by natural 
killer (NK) and T cells (2). IFN-γ primarily signals through the 
Janus kinase (JAK) – signal tranducers and activators of transcrip-
tion (STAT)-1 pathway and primes the secretion of proinflam-
matory cytokines, production of superoxide anions, generation 
of nitrogen and oxygen free radicals and thereby conditions 
macrophages as potent antibacterial effector cells (3, 4). Of note, 
STAT1 is also activated by type I IFNs, which can be produced by 
various cell types including macrophages in bacterial infection 
(5). However, in contrast to IFN-γ, type I IFN is not protective 
and may even exacerbate infection with Listeria monocytogenes 
(Lm), a facultative intracellular bacterium (6, 7).
In addition to cell surface and endosomal Toll-like receptors, 
cytosolic nucleotide oligomerization domain protein (NOD)-
like receptors, in particular NOD2, recognize intracellular bac-
teria such as Lm. Activated NOD2 binds to receptor-interacting 
serine/threonine kinase 2 (RIPK2) (8). RIPK2 undergoes K63 
polyubiquitination resulting in the activation of nuclear fac-
tor kappa-light-chain enhancer of activated B cells (NF-κB) 
and mitogen-activated protein kinases (MAPKs) (9–13). The 
activity of RIPK2 is counter-regulated by the deubiquitinat-
ing enzyme A20, which disassembles K63-linked ubiquitin 
chains from RIPK2 (10). NOD2-dependent RIPK2 activation 
is essential for an effective antibacterial response, since RIPK2-
deficient macrophages have an impaired pathogen control 
(14–16) and RIPK2-deficient mice are highly susceptible to 
listeriosis (17).
Listeria monocytogenes may cause severe infections in preg-
nant women and immunocompromised patients (18). In mice, 
Listeria rapidly home to Kupffer cells, i.e., liver-resident mac-
rophages (19). In addition, uninfected myeloid cell populations 
including macrophages, monocytes, and TNF/iNOS-producing 
dendritic cells are recruited to the site of infection and are crucial 
for the control of listeriosis (20). In macrophages, both NF-κB 
and MAPK induce the synthesis of protective (i) proinflamma-
tory cytokines including IL-6 and IL-12, (ii) ROS, (iii) nitric 
oxide (NO), and (iv) autophagosomes (21–24). The formation of 
autophagosomes is either induced via the NOD2/RIPK2/extra-
cellular signal-regulated kinase (ERK) pathway (25) or NOD2 
independent by the autophagy-related protein 16-1 (ATG16L1) 
(26). In the autophagosomes, phagocytosed Lm are killed by ROS 
(27–29). In further amplification of antibacterial activity, ROS 
activates the STAT1 pathway leading to increased production of 
NO, which reacts with ROS to produce peroxynitrite, an even 
stronger antibacterial molecule (30).
The deubiquitinating enzyme CYLD cleaves K63-linked poly-
ubiquitin chains from specific substrates (31), including tumor 
necrosis factor receptor-associated factors (TRAF)-2, TRAF6, 
transforming growth factor beta-activated kinase 1 (TAK1), B 
cell lymphoma 3 (BCL3), STAT3, nuclear factor kappa B essential 
modulator (NEMO), and retinoic acid inducible gene 1 (RIG-
1) (32–36), and negatively regulates the activation of NF-κB, 
MAPKs, and type I IFN production. In infectious diseases, CYLD 
has a disease-specific effect and CYLD-deficient mice suffer from 
exacerbated Escherichia coli pneumonia and Haemophilus influ-
enzae middle ear infection (37, 38) but are protected against lethal 
Streptococcus pneumoniae and Lm infection (36, 37).
Earlier, we have shown that macrophage-derived IL-6 induced 
STAT3-dependent protective fibrin production by hepatocytes 
in listeriosis (36). However, it remained unclear whether CYLD 
also directly regulated the antibacterial function of infected 
macrophages, in particular, the NOD2-dependent activation of 
NF-κB, MAPKs, and autophagy. Here, we newly identified that 
CYLD inhibits NOD2-dependent antibacterial activity of mac-
rophages by K63 deubiquitination of RIPK2.
resUlTs
cYlD impairs Production of cytokines, 
rOs, and nO and reduces activation of 
nF-κB, erK1/2, and p38MaPK in lm-
infected BMDM
Upon infection with Lm, Cyld−/− BMDM showed no significant 
improvement in pathogen control as compared to WT BMDM 
(Figure 1A, p < 0.05). In good agreement with previous reports 
(39, 40), pretreatment of BMDM with IFN-γ, greatly augmented 
the listericidal activity of BMDM. Importantly, the IFN-γ-
induced listericidal effect was significantly stronger in Cyld−/− as 
compared to WT BMDM. Since CYLD only regulated pathogen 
control upon IFN-γ stimulation, we further focused on the func-
tion of CYLD in IFN-γ-stimulated Lm-infected BMDM.
In addition to pathogen control, the production of listericidal 
ROS and NO as well as the cytokines IL-6 and IL-12 were signifi-
cantly increased in IFN-γ-treated Lm-infected Cyld−/− BMDM 
(Figures 1B–E). To identify the underlying CYLD-regulated sign-
aling pathways, the activation of NF-κB, ERK1/2, and p38MAPK 
were analyzed by WB in IFN-γ-stimulated Lm-infected BMDM. 
As displayed in Figure  1F, Cyld−/− BMDM showed enhanced 
activation of NF-κB as indicated by increased phosporylation of 
p65 and IκB-α. In addition, activation of ERK1/2 and p38MAPK 
were augmented in Cyld−/− BMDM. In contrast, stimulation with 
IFN-γ only was insufficient to induce activation of these signaling 
pathways.
cYlD impairs activation of sTaT1
Mice with macrophage-specific deletion of STAT1 are susceptible 
to listeriosis (41). Since IFN-γ augments bactericidal activity and 
NO production of Lm-infected macrophages [Figure  1A (39, 
40)] and the immunostimulatory activity of IFN-γ is mediated by 
the transcription factor STAT1, we studied the impact of CYLD 
on the activation of STAT1 in Lm-infected IFN-γ-stimulated 
BMDM. Within 30 min post infection, the phosphorylation of 
cytoplasmic and nuclear STAT1 (Y701) and STAT1 (S727) was 
increased in Cyld−/− as compared to WT BMDM (Figure 2A). 
To study how CYLD reduces STAT1 activation and nuclear 
accumulation in IFN-γ-stimulated Lm-infected BMDM, 
we analyzed whether CYLD might directly bind to STAT1. 
However, immunoprecipitation experiments showed that CYLD 
FigUre 1 | cYlD impairs pathogen control and decreases cytokine production and activation of nF-κB and MaP kinases. WT and Cyld−/− BMDM 
(1 × 106cells/group), stimulated with IFN-γ (100 U/ml) for 24 h followed by infection with Lm (MOI 5:1). (a) The bacterial load was determined in 1 × 106 IFN-γ-
stimulated and unstimulated Lm-infected WT and Cyld−/− BMDM 24 h p.i. (B) Levels of intracellular ROS were analyzed by flow cytometry in 1 × 106 uninfected (0 h 
p.i.) and infected (1, 6, 24 h p.i.) WT and Cyld−/− BMDM. (c) The amount of NO was measured in the supernatant of 1 × 106 uninfected and infected WT and 
Cyld−/− BMDM colorimetrically using a Griess assay kit. (D,e) IL-6 (D) and IL-12 (e) were determined in the supernatant of 1 × 106 Lm-infected WT and Cyld−/− 
BMDMs by flow cytometric bead array. (F) Proteins were isolated from 1 × 106 uninfected and infected WT and Cyld−/− BMDM at the indicated time points and 
stained with antibodies specific for CYLD, p-p38, p38, p-ERK1/2, ERK1/2, p-IκB-α, p-p65, and p65. GAPDH was used as loading control. In (a–e), data represent 
the mean + SD from triplicate wells. In (a–F), data from one of the three representative experiments are shown.
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FigUre 2 | cYlD diminishes activation of sTaT1 upon stimulation with iFn-γ. (a–c) 1 × 106 WT and Cyld−/− BMDM were stimulated with IFN-γ (100 U/ml) 
for 24 h. Thereafter, the indicated groups of BMDM were additionally infected with Lm (MOI 5:1) for 24 h. Proteins were isolated from uninfected (0 min p.i.) and 
infected (30, 60 min p.i.) BMDM as indicated. (a) Proteins were isolated from the cytoplasm and nucleus of BMDM respectively at the indicated time points after 
infection. WBs were stained with anti-tubulin and anti-histone deacetylase (HDAC) as marker proteins for the cytoplasm and nucleus, respectively. In addition to total 
STAT1, phosphorylation of STAT1 at position Y701 and S727, respectively, was analyzed by WB. (B) BMDM were either left untreated or treated with IKK inhibitor 
(1 μM) beginning in parallel to IFN-γ treatment. Proteins were isolated at the indicated time points and WB analysis for p-65, p-p-65, STAT1, p-STAT1 (Y701), 
p-STAT1 (S727), and GAPDH was performed. (c) IFN-γ-stimulated, -uninfected, and -infected BMDM were either treated with control IgG or anti-IFNAR1 antibody 
(30 μg/ml) beginning 30 min before infection with Lm. Proteins were isolated at the indicated time points and WB analysis for p-65, p-p-65, STAT1, p-STAT1 (Y701), 
p-STAT1 (S727), and GAPDH was performed. In (a–c), data represent one of the two independent experiments.
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and STAT1 did not interact with each other (data not shown). 
Importantly, the inhibition of NF-κB activity by an IKK inhibitor 
decreased p-STAT1 to equally low levels in both Lm-infected WT 
and Cyld−/− BMDM indicating that the activation of STAT1 was 
dependent on the augmented Listeria-induced NF-κB activation 
(Figure 2B).
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In listeriosis, type I IFNs, which also activate STAT1, 
are mainly produced by macrophages and exacerbate the 
diseases (5–7). Therefore, we studied the effect of type I IFNs 
on the CYLD-mediated suppression of STAT1 activation in 
Lm-infected IFN-γ-stimulated BMDM. Blocking of IFNAR1 by 
IFNAR1-specific antibodies in Lm-infected IFN-γ-stimulated 
BMDM decreased p-STAT1 (Y701) and p-STAT1 (S727) levels 
in Lm-infected WT and Cyld−/− BMDM without abolishing 
the strongly enhanced STAT1 activation of Cyld−/− BMDM 
(Figure 2C). Thus, in addition to IFN-γ, the activation of STAT1 
was partially dependent on autocrine type I IFN-mediated acti-
vation of STAT1 (Figure 2C).
cYlD impairs riPK2-Mediated 
activation and antibacterial Function  
of BMDM
Since RIPK2 activates the canonical NF-κB and ERK pathways, 
upon intracellular recognition of Lm by the NOD2 receptor, 
we studied the impact of CYLD on RIPK2 expression in IFN-
γ-stimulated Lm-infected BMDM. In IFN-γ-stimulated and 
Lm-infected BMDM, RIPK2 protein was increased in Cyld−/− 
as compared to WT BMDM (Figure  3A). To study whether 
increased RIPK2 levels in Cyld−/− BMDM led to the increased 
activation of NF-κB and MAPKs pathways, IFN-γ-stimulated 
WT and Cyld−/− BMDM were treated with RIPK2 and control 
siRNA, respectively, for 48 h prior to Lm infection. WB analysis 
showed an efficient knockdown of RIPK2 in RIPK2-siRNA-
treated BMDM 24 h p.i., whereas treatment with control siRNA 
did not influence RIPK2 protein levels (Figure  3B). RIPK2 
knockdown caused a strong decrease of p-IκB-α (Figure  3B) 
and p-ERK (Figure  3B) and diminished differences in the 
expression levels of both molecules in Cyld−/− and WT BMDM. 
In addition, RIPK2-siRNA-treatment of IFN-γ-stimulated 
Lm-infected BMDM significantly reduced IL-6 (Figure  3C), 
ROS (Figure 3D), and NO levels (Figure 3E) in both Cyld−/− and 
WT BMDM. Consequently, siRNA-mediated RIPK2 inhibition 
significantly increased colony-forming units (CFUs) in RIPK2-
siRNA-treated Cyld−/− and WT BMDM (Figure 3F). Thus, the 
improved immune response in Lm-infected Cyld−/− BMDM is 
RIPK2 dependent.
K63 Deubiquitination of riPK2 by cYlD
To study whether CYLD directly regulates RIPK2 in Lm-infected 
BMDM, we immunoprecipitated CYLD from Lm-infected IFN-
γ-stimulated WT and Cyld−/− BMDM. WB analysis of immuno-
precipitates detected CYLD and RIPK2 only in WT BMDM but 
not in Cyld−/− BMDM indicating that CYLD interacts with RIPK2 
(Figure 4A). Transfection of Cyld−/− BMDM with MYC-DDK-
RIPK2, HA-CYLD (CYLD WT), and catalytically inactive CYLD 
(CYLD C/S) followed by immunoprecipitation of DDK-RIPK2 
further showed that WT CYLD reduced K63 ubiquitination 
of RIPK2 (Figure  4B). Catalytically inactive CYLD interacted 
with RIPK2 but failed to reduce K63 ubiquitination of RIPK2 
(Figure 4B).
cYlD regulates erK1/2-Mediated 
Production of antibacterial effector 
Molecules, autophagy, and control of lm
Since NOD2-mediated RIPK2 activation results in the activation 
of ERK (Figure 1F), we further studied the impact of CYLD on 
ERK1/2-dependent pathogen control and production of ROS and 
NO. Inhibition of ERK by pretreatment of BMDM with U0126, 
an ERK1/2 inhibitor, increased CFU and reduced the levels of 
ROS (Figure 5A) as well as NO (Figure 5B) in BMDM from both 
mouse strains. Whereas ERK1/2 inhibition abolished differences 
between WT and Cyld−/− mice with respect to CFU and ROS, NO 
levels were still significantly increased in Cyld−/− mice.
Autophagy is an intrinsic defense mechanism against Lm and, 
therefore, we further investigated whether CYLD-dependent 
RIPK2 and ERK1/2 activation influences the formation of 
autophagosomes. WB for the autophagosome marker LC3B-II 
indicated increased autophagosome formation in Cyld−/− BMDM 
(Figure 5C). Fluorescence microscopy results showed increased 
number of autophagosomes (green) (Figures  5D,E) in Cyld−/− 
BMDM accompanied by reduced Lm burden (red) (Figure 5D). 
Furthermore, the enhanced formation of autophagosome in 
Cyld−/− BMDM was abolished upon knockdown of RIPK2 by 
siRNA (Figures 5D,E) as well as inhibition of the downstream 
molecule ERK1/2 (Figures 5D,E). The reduction in autophago-
mes resulted in increased Lm load in BMDM from both groups 
(Figure  5D) indicating that CYLD inhibits the formation of 
autophagosomes by regulating RIPK2-mediated ERK1/2 expres-
sion. In accordance to the reduced production of ROS, NO, and 
autophagosomal killing of Lm in ERK-inhibitor-treated WT 
and Cyld−/− BMDM, inhibition of ERK resulted in significantly 
increased CFUs in both groups (Figure 5F).
DiscUssiOn
The present study identified CYLD as a novel and important 
inhibitor of RIPK2-dependent protective immune responses in 
Lm-infected murine macrophages. Activation of RIPK2 by the 
Lm-sensing intracellular pattern-recognition receptor NOD2 
is essential for the downstream stimulation of the NF-κB and 
MAPK pathways (42, 43), NOD2-induced immune responses 
in macrophages (25) and the control of listeriosis in  vivo (17). 
Previous studies have shown that CYLD limited RIPK2-mediated 
activation of NF-κB by removing K63-polyubiquitin chains from 
NEMO (8, 44). In addition to NEMO, the proinflammatory func-
tion of RIPK2 is also dependent on its K63 polyubiquitination. 
Although multiple E3 ligases including Pellino-3, ITCH, cellular 
inhibitor of apoptosis (cIAP)-1, cIAP2, X-linked apoptosis of 
protein (XIAP) and TRAF2, TRAF5, and TRAF6 (9, 11–13, 45) 
perform K63 polyubiquitination of RIPK2, the only counter-
regulatory RIPK2 K63-deubiquitinating enzyme identified so far 
is A20 (10). Here, we demonstrate that CYLD also directly binds 
to RIPK2 and cleaves K63-polyubiquitin chains from RIPK2 
in Lm-infected macrophages resulting in a reduced activation 
of NF-κB, p38 MAPK, and ERK1/2 and, consequently, in an 
impaired control of Lm in macrophages.
FigUre 3 | cYlD-mediated inhibition of nF-κB and MaP kinases activation is dependent on riPK2. WT and Cyld−/− BMDM were cultivated and the 
indicated subgroups of BMDM (1 × 106/well) were transfected with RIPK2 and control siRNA, respectively, beginning 48 h before stimulation with IFN-γ (100 U/ml, 
all groups of BMDM). After 24 h of IFN-γ-stimulation, the indicated groups of BMDM were infected with Lm (MOI 5:1) for the indicated time points or left untreated 
(0 h p.i.). (a) Proteins were isolated from indicated groups of 1 × 106 uninfected and Lm-infected BMDM and analyzed for RIPK2 and GAPDH protein expression by 
WB. In this experiment, the same proteins were used as in Figure 1F. (B) BMDMs were treated with siRNA and infected with Lm as indicated. Proteins were 
isolated and analyzed by WB for RIPK2, p-ERK1/2, p-IκBα, and GAPDH protein expression. (c) The indicated groups of RIPK2 and control siRNA-treated WT and 
Cyld−/− BMDM were infected with Lm or left uninfected. The supernatant of BMDM cultures was harvested before infection (0) or 24 h post infection (p.i.). IL-6 was 
determined in the supernatant by flow cytometry using cytometric bead array. Data show the mean + SD of triplicate wells per group. (D) BMDMs were transfected 
with RIPK2 and control siRNA and infected with Lm as indicated. Intracellular ROS production of 1 × 106 WT and Cyld−/− BMDM was analyzed by flow cytometry 
employing a ROS detection kit. BMDM were analyzed before infection (0 h p.i.) and at the time point of infection (1 h p.i. and 24 h p.i.). Data show the mean + SD of 
triplicate wells per group. (e) The supernatant of the indicated groups of RIP2K and control siRNA treated, uninfected, and infected WT and Cyld−/− BMDM 
(1 × 106 cells) was harvested before and 24 h p.i. NO was determined photometrically using a Griess assay kit. Data show the mean + SD of triplicate wells per 
group. (F) Twenty-four hours p.i., the bacterial load was determined in Lm-infected WT and Cyld−/− BMDM (1 × 106 cells), which were treated with RIPK2 and 
control siRNA as indicated. Data show the mean + SD of triplicate wells per group. In (a–F), data represent one of the two independent experiments with similar 
results.
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FigUre 4 | cYlD cleaves K63-polyubiquitin chains from riPK2.  
(a) Proteins from 1 × 106 IFN-γ stimulated, infected (MOI 5:1, 24 h after 
infection) and uninfected WT and Cyld−/− BMDM were immunoprecipitated 
with CYLD antibody. Immunoprecipitates were stained for CYLD and RIPK2. 
GAPDH was used as loading control. (B) Cyld−/− BMDM (1 × 106 cells) were 
transfected with MYC-DDK-RIPK2, HA-CYLD (WT), and mutant HA-CYLD 
(C/S), which lacks catalytic activity, as indicated. After 24 h of infection, total 
lysates were immunoprecipitated with anti-DDK. Immunoprecipitates were 
stained for the indicated proteins. Beads plus lysate without antibody before 
immunoprecipitation (B + L), beads plus DDK antibody without lysate (B + A), 
and GAPDH were used as control. In (a,B), data represent one of the two 
independent experiments.
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In addition to listeriosis, RIPK2 plays essential protective 
role upon infection with the intracellular bacteria Legionella 
pneumophila, Chlamydophila pneumonia, and Mycobacterium 
tuberculosis (15, 17, 46). In sharp contrast, RIPK2 promotes 
inflammation and lethality during infection with the Gram-
negative bacteria Pseudomonas aeruginosa and E. coli due to 
excessive activation of NF-κB and MAPK (47). Interestingly, 
Cyld deficiency also increases susceptibility to infection with E. 
coli and H. influenzae due to immunopathology induced by the 
hyperactivation of the same signaling pathways (37, 38), whereas 
it protects from lethal listeriosis (36). Thus, the underlying infec-
tion determines the impact of RIPK2 and CYLD on the outcome 
of the disease and our identification of a direct inhibition of 
RIPK2 by CYLD provides a mechanistical explanation of the 
antagonistic effects of these two signaling molecules.
The crucial importance of the CYLD/RIPK2 interaction for the 
reduction of protective anti-Lm immune responses is shown by the 
complete abolishment of the protective effect of Cyld deficiency 
by RIPK2 inhibition. In the absence of RIPK2, Lm-infected WT, 
and Cyld−/− macrophages produced less ROS and NO, showed 
reduced autophagy and, finally, exhibited diminished control of 
the pathogen without any significant differences between Cyld-
competent and -deficient BMDM.
CYLD regulates the NF-κB-dependent production of anti-
bacterial ROS and NO in macrophages (36, 48). Here, we also 
demonstrate that CYLD also inhibits ERK1/2-dependent ROS 
production. However, compared to NF-κB-dependent ROS 
production, the effect of ERK1/2 inhibition on reduction of ROS 
was lower (≈50%) in both WT and Cyld−/− BMDM. In addition, 
NO production was significantly reduced by ERK1/2 inhibition 
in both Lm-infected WT and Cyld−/− BMDM. In contrast to 
ROS, ERK inhibition did not abolish the increased production 
of NO in Cyld−/− BMDM. Thus, both the increased NF-κB and 
ERK1/2 activation in Cyld−/− BMDM contributes to the increased 
ROS and NO production, although NF-κB seems to be the more 
potent regulator. This is also illustrated by the more than 100-fold 
increase of CFU in both NF-κB inhibited WT and Cyld−/− BMDM 
as compared to a <10-fold increase in macrophages with ERK1/2 
inhibition (Figure 5F) (36).
Autophagy is an essential cell intrinsic mechanism to combat 
intracellular Listeria and RIPK2 is known to regulate autophagy 
via ERK activation (25). Here, we identify for the first time that 
CYLD also impairs autophagosome formation in Lm-infected 
macrophages (Figures  5D–E). Inhibition of RIPK2 and ERK 
caused a reduction in autophagosome formation accompanied 
by increased Lm burden in both WT and Cyld−/− BMDM. Thus, 
CYLD impairs production of antibacterial effector molecules and 
autophagosome formation, which all contribute to the impaired 
pathogen control.
The convergence of type I and type II IFN signaling on the 
level of STAT1 places this signaling molecule in a central position 
in antibacterial defense of macrophages (41).
In good agreement with previous studies (39, 40), IFN-γ pres-
timulation of macrophages greatly augmented their capacity to 
control Lm. In extension and importantly, the protective effect of 
Cyld deficiency on the control of Lm was completely dependent 
on IFN-γ prestimulation of macrophages. IFN-γ prestimula-
tion of WT and Cyld−/− BMDM without infection resulted in 
an equally weak activation and nuclear translocation of STAT1, 
a critical IFN-γ-induced transcription factor (Figure  2A). In 
accordance with the CYLD-independent activation of STAT1 by 
IFN-γ, we could not detect a direct interaction of CYLD with 
STAT1. In sharp contrast, STAT1 activation was much stronger 
in Cyld−/− BMDM upon additional Lm infection. This suggests 
an indirect regulation of STAT1 activation by NOD2/RIPK2-
dependent immune responses. In fact, we could identify that 
inhibition of NF-κB abolished the increased STAT1 activation 
in Lm-infected IFN-γ-stimulated Cyld−/− BMDM (Figure 2B). 
This indirect regulation of STAT1 signaling by CYLD resembles 
the function of the deubiquitinating enzyme A20, which also 
inhibits STAT1 activation indirectly by suppressing NF-κB 
activation (49).
FigUre 5 | erK-dependent production of anti-listerial effector molecules and autophagy protects against Listeria infection of BMDM. WT and 
Cyld−/− BMDM (1 × 106/well) were cultivated and stimulated with IFN-γ (100 U/ml) for 24 h. Thereafter, the indicated groups of BMDM were infected with Lm (MOI 
5:1) or left uninfected (0 h p.i.). (a) IFN-γ-stimulated BMDM were either untreated or treated with the ERK inhibitor U0126 (1 μM) beginning 2 h before infection. 
Intracellular ROS was determined by flow cytometry using a ROS detection kit at the indicated time points. Data show the mean + SD of triplicate wells per group. 
(B) Uninfected and infected, IFN-γ-stimulated WT, and Cyld−/− BMDM were treated with the ERK inhibitor U0126 (1 μM) beginning 2 h before infection as indicated. 
The supernatant was harvested before and 24 h p.i. NO was determined photometrically in the supernatant using a Griess assay kit. Data show the mean + SD of 
triplicate wells per group. (c) Proteins were isolated from IFN-γ-stimulated, uninfected (0 h p.i.), and infected (2 h p.i.) WT and Cyld−/− BMDM and WB analysis for 
the autophagosomal marker LC3B-II and GAPDH was performed. LC3B-II expression was determined using a densitometer and data show the mean of three WB 
performed with independent samples. (D) Immunofluorescence images from uninfected and Lm-infected WT and Cyld−/− BMDM are shown. Cells (5 × 105 BMDM 
per slide) were either untreated or treated with RIPK2 siRNA (D3, beginning 48 h before infection) or the ERK inhibitor U0126 (D4, 1 μM, beginning 2 h before 
infection). BMDM were stained for Listeria (red), LC3B-II (green), and the nucleus (DAPI, blue). (e) Two hours p.i., the number of LC3B-II puncta per cell from the 
experimental groups shown in (D) was determined microscopically. Data show the mean + SD of three slides and 100 BMDM/slide per group. (F) CFUs were 
determined in 1 × 106 Lm-infected WT and Cyld−/− BMDM, which were either untreated or treated with ERK inhibitor U0126 (10 μM) beginning 2 h before infection. 
Data show the mean + SD of triplicate wells per group. In (a–F), data represent one of the two independent experiments.
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In addition to type II IFN, type I IFNs play an important role in 
the macrophage-mediated immune responses. The convergence 
of type I and type II IFN signaling on the level of STAT1 places this 
signaling molecule in a central position in antibacterial defense of 
macrophages (41). Previously, it has been shown that type I IFNs 
synergistically activates with NF-κB an anti-listerial response in 
Lm-infected macrophages (50), in good agreement, inhibition 
of the IFNAR resulted in a reduced activation of STAT1 in both 
WT and Cyld−/− macrophages (Figure 2C). Thus, activation of 
the NOD2/RIPK2/NF-κB pathway and endogenous production 
of type I IFN cooperatively regulated the activation of STAT1 
and gene transcription of proinflammatory and antibacterial 
mediators.
Taken together, our study identifies CYLD as a new interaction 
partner and regulator of RIPK2 kinase signaling pathways and as 
an inhibitor of anti-listerial immune responses of macrophages. 
Before, we have shown that CYLD inhibits protective fibrin pro-
duction by hepatocytes in listeriosis (36). Thus, CYLD impairs 
the outcome of the infection by inhibiting several non-redundant 
protective host responses. This places CYLD in an attractive posi-
tion as a therapeutic target molecule in severe infections with Lm 
and, potentially, other intracellular bacteria. In addition, it will 
be important to develop conditional CYLD-deficient mice to 
decipher the importance of CYLD in individual cell types under 
infectious disease conditions.
MaTerials anD MeThODs
ethics statement
All animal experiments were in compliance with the 
German animal protection law in a protocol approved by the 
Landesverwaltungsamt Sachsen-Anhalt (file number: 203.h-
42502-2-901, University of Magdeburg).
animals
Age- and sex-matched animals were used for the experiments. 
C57BL/6 WT were obtained from Janvier (Le Genest Saint Isle, 
France) and C57BL/6 Cyld−/− mice were kindly provided by Dr. 
Ramin Massoumi (Department of Laboratory Medicine, Malmö, 
Sweden) (34). All animals were kept under conventional condi-
tions in an isolation facility of the Otto-von-Guericke University 
Magdeburg. Experiments were approved and supervised by local 
governmental institutions.
Listeria monocytogenes
Listeria monocytogenes (EGD strain) was grown in brain–heart 
infusion broth (Merck, Darmstadt, Germany) and aliquots of 
log-phase cultures were stored at −80°C. For infection of BMDM, 
fresh log phase cultures were prepared from frozen stock.
Bone Marrow-Derived Macrophages
Freshly prepared BMDM were used for each experiment. Femur 
and tibia were aseptically removed from mice, the bone ends 
were cut off, and the bone marrow cells were flushed out using 
PBS (4–8°C; Gibco, Darmstadt, Germany). The cell suspension 
was washed twice with PBS by centrifugation (490 ×  g, 5  min) 
and cultured in Petri dishes (ø 85  mm, Sarstedt, Numbrecht, 
Germany) in Dulbecco’s modified Eagle’s medium with high 
glucose and l-glutamine (DMEM) supplemented with 10% 
FCS, 1% non-essential amino acids (all from PAA, Coelbe, 
Germany), 1% glutamine (Biochrom, Berlin, Germany), 50 μM 
2- mercaptoethanol (Gibco, Darmstadt, Germany), and 20 ng/ml 
macrophage colony-stimulating factor (M-CSF) (PeproTech, 
Hamburg, Germany) for 3 days. Medium was changed on day 3 and 
non-adherent cells were removed by washing with PBS. Adherent 
BMDM were harvested at day 6 and used for experiments. The purity 
of the cultured macrophages ranged from 95 to 99%, as determined 
by flow cytometry using the macrophage-specific markers CD11b 
and F4/80 (F4/80 eFluor450 (clone: BM8)) and CD11b APC (clone: 
M1/70; both eBioscience, Frankfurt, Germany).
In vitro infection of BMDM with lm
About 1 × 106 BMDM were stimulated in six-well plates (Greiner 
bio-one, Frickenhausen, Germany) with IFN-γ (100  U/ml) 
(PeproTech, Hamburg, Germany), a dose previously standard-
ized by us (36) for 24 h. Thereafter, stimulated and unstimulated 
BMDM were infected with Lm at a multiplicity of infection 
(MOI) of 5:1 in DMEM supplemented with 10% FCS, 1% non-
essential amino acids, 1% glutamine, 50 μM 2-mercaptoethanol, 
and 20 ng/ml M-CSF. For infection, Lm were thawed from frozen 
stocks (−80°C) and added to brain–heart infusion broth. The 
optical density of log-phase cultures were determined using a 
photometer (Eppendorf, Hamburg, Germany). Cultures with an 
optical density of 0.1, which corresponds to a dose of 1 × 108 Lm/
ml according to a previously established standard growth curve, 
were pelleted by centrifugation (870 × g, 4°C, 10 min) and the 
multiplicity of infection MOI was adjusted to 5:1 in DMEM 
supplemented with 10% FCS, 1% non-essential amino acids, 1% 
glutamine, and 50 μM 2-mercaptoethanol. In each experiment, 
the bacterial dose used for infection was controlled by plating 
an inoculum on brain–heart infusion agar and counting colonies 
after incubation at 37°C for 24 h.
After 1 h of infection (37°C, 5% CO2), 30 μg/ml gentamicin 
(Sigma-Aldrich) was added for additional 3  h to kill extracel-
lular bacteria. Thereafter, infected BMDM were washed twice 
with PBS and further cultivated in DMEM supplemented with 
15 μg/ml gentamicin for the indicated time points. For inhibition 
of NF-κB, BMDM were treated with IKK inhibitor VII (1 μM; 
Calbiochem, Darmstadt, Germany) beginning 24 h before infec-
tion (concentration and incubation time were pretested before 
usage). For the inhibition of ERK, BMDM were treated with the 
ERK inhibitor U0126 (1 μM; Calbiochem) beginning 2 h before 
infection according to the manufacturer’s recommendation. The 
inhibitors were dissolved in DMSO (5 mg U0126/ml; 10 mg IKK 
inhibitor VII/ml). The final concentration of DMSO used in the 
cultures was 0.1%. For the inhibition of IFNAR1, BMDM were 
pretreated with either anti-IFNAR1 or control IgG (30 μg/ml) 
30 min before infection according to the manufacturer’s recom-
mendation (BioLegend, Fell, Germany).
colony-Forming Units
At the indicated time points p.i., Lm-infected BMDM cultures 
were centrifuged (5 min, 490 × g) and the medium was discarded. 
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Thereafter, the cells were washed with PBS to remove traces of 
remaining antibiotics. After centrifugation (5 min, 490 × g) and 
removal of PBS, the cell pellets were lysed in 0.1% Triton-X-100 
and serial dilutions were plated on brain–heart infusion agar in 
Petri dishes (ø 85 mm; Merck, Darmstadt, Germany). Bacterial 
colonies were counted microscopically using a grid plate after 
incubation at 37°C for 24 and 48 h. The counting was conducted 
blindly and 16 fields were counted.
Protein isolation and Western Blot
Interferon gamma-stimulated Lm-infected BMDM were 
washed in PBS and resuspended in 4–8°C cold lysis buffer 
containing 50  mM Tris–HCl (pH 7.4), 5  mM EDTA, 100  mM 
NaCl, 1% Triton-X-100, 10% glycerol, 10  mM KH2PO4, 0.5% 
Na-deoxycholate, 1 mM phenylmethanesulfonyl fluoride 1 mM 
NaF, 1 mM Na4O7P2, 1 mM Na3VO4 and aprotinin, leupeptin, and 
pepstatin (1 μg/ml each) (all reagents from Sigma, Taufkirchen, 
Germany) for 30 min and centrifuged (19,000 × g, 4°C, 10 min). 
The supernatant was collected and the protein concentration 
was determined by a commercial protein assay kit (Bio-RAD, 
Munich, Germany). A 1× lane marker reducing sample buffer 
(Thermo Scientific, Dreieich, Germany) was added to the samples 
and proteins were denatured at 99°C for 5 min. Equal amounts of 
proteins were separated on SDS-polyacrylamide gels (6–12%) and 
transferred semidry (220 mA, 60 min) on polyvinylidene fluoride 
membranes, preactivated in methanol. Unspecific binding of 
antibodies was blocked by incubating the membranes with either 
Blotto B [1% milk powder plus 1% bovine serum albumin (BSA)], 
5% milk powder, or 5% BSA for 1 h. The proteins were stained for 
GAPDH, STAT-1, phospho-STAT1 S727, phospho-STAT1 Y701, 
phospho-p65, p65, phospho-p38, p38, phospho-IκBα, phospho-
ERK1/2, ERK1/2, CYLD, LC3B, ubiquitin, K63-linkage-specific 
polyubiquitin (all antibodies from Cell Signaling Technology, 
Frankfurt, Germany), RIPK2 (Abcam, Cambridge, UK), tubulin 
(Sigma-Aldrich, Steinheim, Germany), and HDAC1 (Santa Cruz, 
Heidelberg, Germany). Primary antibodies were used at a dilu-
tion of 1:1000 in specific blocking medium as recommended by 
the supplier. Following overnight incubation, membranes were 
washed three times using Tris-buffered saline with 0.1% Tween 
20 (TBST) for 10  min each and further incubated with 1:1000 
diluted anti-mouse or anti-rabbit secondary antibodies (Dako, 
Hamburg, Germany) for 1  h. The blots were washed for three 
times in TBST 10 min each and developed using an ECL Plus kit 
(GE Healthcare, Freiburg, Germany). For quantification of pro-
tein intensities by densitometry, WB images were captured using 
the Intas Chemo Cam Luminescent Image Analysis system® 
(INTAS Science Imaging Instruments, Göttingen, Germany) and 
analyzed with the LabImage 1D software® (Kapelan Bio-Imaging 
Solutions, Leipzig, Germany).
Transfection of BMDM
Bone marrow-derived macrophages were transiently transfected 
with hemagglutinin (HA)-CYLD WT, HA-CYLD C/S (catalyti-
cally inactive CYLD), and MYC-DDK RIPK2 (Origene, Rockville, 
MD, USA) plasmids, respectively, as indicated using Neon 
transfection system (Invitrogen, Darmstadt, Germany). PBS 
(without Ca2+ and Mg2+) was added to 1 × 107 BMDM followed by 
centrifugation (5 min, 490 × g) and removal of the supernatant. 
The cell pellet was resuspended in 1 ml of resuspension buffer R 
(provided in the Neon transfection system kit). The transfection 
was performed according to the manufacturer’s instructions 
using a single pulse of 1000 V for 20 ms. The transfected BMDM 
were plated in six-well plates (Greiner bio-one, Frickenhausen, 
Germany) containing culture medium (DMEM supplemented 
with 10% FCS, 1% non-essential amino acids, 1% glutamine, 
50 μM 2-mercaptoethanol, and 20 ng M-CSF/ml) and incubated 
at 37°C for 24 h before using them for experiments. The efficiency 
of transfection was controlled by WB for the indicated proteins.
immunoprecipitation
Uninfected and IFN-γ-stimulated Lm-infected BMDM as well as 
Cyld−/− BMDM transfected with MYC-DDK-RIPK2, HA-CYLD 
(WT), and mutant HA-CYLD (C/S) were lysed on ice using the 
same protein lysis buffer as described above in “Protein isola-
tion and Western Blot.” In a preclearing phase, Gamma Bind™ 
G Sepharose™ beads (GE Healthcare Europe GmbH, Freiburg 
Germany) were incubated with cell lysates under continuous 
shaking at 4°C for 30 min. The beads were removed by centrifuga-
tion (10 min, 10,000 × g, 4°C) and equal amounts of lysates were 
incubated with anti-RIPK2 (1:100) and anti-CYLD (1:200) antibod-
ies, respectively, at 4°C overnight. The immune complexes were 
captured by incubating with fresh Gamma Bind™ G Sepharose™ 
beads at 4°C overnight. The beads were then washed three times 
with PBS by pulse centrifugation (1000 × g, 30 s). The pellet con-
taining the Gamma Bind™ G Sepharose™ immune complexes was 
resuspended in 1× lane marker reducing sample buffer and boiled at 
99°C for 5 min. Thereafter, samples were centrifuged (1000 × g, 30 s), 
the supernatant was collected and used to detect RIPK2, CYLD, K63 
ubiquitin, by WB. GAPDH was used as the input control.
Measurement of nO
The concentration of NO in the cell culture medium was meas-
ured using a Griess Assay Kit (Promega, Mannheim, Germany) 
according to the manufacturer’s instructions. In brief, the cells 
were centrifuged (490 × g, for 5 min) to harvest the supernatant. 
Triplicates of diluted standard and supernatant (50 μl each) were 
added to the wells of a 96-well flat-bottom plate (Greiner bio-one, 
Frickenhausen, Germany). Subsequently, 50 μl of sulfanilamide 
solution was dispensed to the standard and the experimental 
samples and incubated in the dark for 10 min. Thereafter, 50 μl 
of N-(1-naphthyl) ethylenediamine solution was added to all 
samples, which were further incubated in the dark for 10 min. 
The NO concentration was determined by measuring samples 
at 540  nm using a Synergy® microplate reader (Biotek, Berlin, 
Germany) within 30 min.
rOs/rni Detection
The intracellular production of reactive oxygen and nitrogen 
species (ROS/RNI) was determined with a total ROS detection 
kit (Enzo Life Science, Lörrach, Germany). In brief, 1  ×  106 
freshly prepared BMDM were infected with Lm at an MOI 
of 5:1. After infection, the cells were centrifuged (490 ×  g, for 
5  min), the supernatant was discarded and the cell pellet was 
washed twice with 2 ml of 1× washing buffer. Thereafter, the cell 
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pellet was resuspended in 500 μl detection solution (500 μl 1× 
washing buffer + 0.1 μl detection reagent) and incubated in the 
dark at 37°C for 30 min. BMDM stimulated with pyocyanin for 
30 min were used as a positive control. BMDM stimulated with 
N-acetyl-l-cystein for 1 h were used as the negative control. The 
samples were analyzed by flow cytometry using a FACS Canto 
II (BD, Heidelberg, Germany). Enhanced ROS production was 
detected as an increase in the mean fluorescence (490/525 nm) of 
the samples over the control.
cytometric Bead array
The level of IL-6 and IL-12/IL-23/p40 in the supernatant of the 
BMDM cell cultures were analyzed by flow cytometry using the 
cytometric bead array (CBA) from BD Biosciences (Heidelberg, 
Germany) using the manufacturer’s protocol. The cells were cen-
trifuged (490 × g, for 5 min) to harvest the supernatant. Cytokine 
concentration in the supernatant was determined by adding 50 μl 
of cytokine-specific capture bead mixture to 50 μl of supernatant 
and standard tubes. Phycoerythrin (PE) detection agent (50 μl) 
was added to each sample and incubated in the dark at 4°C for 2 h. 
The samples were washed with 1 ml washing buffer, centrifuged at 
200 × g for 5 min and, thereafter, resuspended in washing buffer 
(300 μl). The cytokine levels were measured using a FACS Canto 
II (BD, Heidelberg, Germany) and analyzed with FCAP Array™ 
software (version 3, BD Biosciences).
In vitro sirna Treatment
About 30  pmol siRNA [predesigned RIPK2 siRNA or silencer 
negative control siRNA from Ambion (CA, USA)] and 18 μl of 
Lipofectamine® RNAiMAX (Invitrogen, Darmstadt, Germany) 
were diluted separately in 150 μl Opti-MEM serum-free medium 
each. The siRNA and Lipofectamine were mixed at a ratio of 1:1 
and incubated for 5 min at room temperature. A total of 250 μl 
of the siRNA–Lipofectamine mixture was added to each well in 
a six-well plate containing 1 × 106 BMDM and incubated at 37°C 
for 48 h. The efficiency of siRNA-mediated RIPK2 silencing was 
controlled by WB.
immunofluorescence
About 5 ×  105 BMDM were cultured on flamed coverslips in 
12-well plates (Greiner bio-one, Frickenhausen, Germany). 
BMDM were infected with Lm as described earlier. At the indi-
cated time points after infection, the coverslips were fixed in 4% 
paraformaldehyde (Roth, Karlsruhe, Germany) for 10 min and 
washed three times with PBS for 10  min each. The cells were 
then permeabilized in 0.1% Triton-X-100 solution for 7 min and 
blocked in 10% goat serum, 0, 5% BSA, 0.3% Triton-X-100, and 
5% sucrose for 45  min. For staining, mouse anti-Lm antibody 
(BioRad, Munich, Germany) and rabbit anti-mouse LC3B 
antibody (Cell Signaling Technology, Frankfurt, Germany) were 
used at dilution of 1:200 in blocking medium and incubated with 
constant shaking in the dark overnight. The coverslips were then 
washed three times with PBS for 10 min each and incubated with 
1:200 diluted Alexa Flour® 488 goat anti-rabbit and Alexa Flour® 
594 goat anti-mouse antibody, respectively (both from Invitrogen, 
Darmstadt, Germany) at room temperature for 1 h. Thereafter, 
the coverslips were washed three times with PBS for 10 min each. 
The coverslips were air-dried and mounted on ethanol-cleaned 
slides with ProLong® Gold antifade reagent containing DAPI 
(Invitrogen) and the immunofluorescence was captured using 
Zeiss observer Z.1 microscope (Carl Zeiss GmbH, Oberkochen, 
Germany).
statistics
Statistical significance was determined using the two-tailed 
Student’s t-test or non-parametric Mann–Whitney rank-sum 
test. All experiments were performed at least twice. p Values of 
<0.05 were considered significant.
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